MDXHealth SA (NASDAQ:MXDHF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, September 15th. The firm presently has a $6.25 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 5.93% from the stock’s current price.

According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “

Shares of MDXHealth SA (MXDHF) opened at 5.90 on Friday. The company’s market cap is $294.70 million. MDXHealth SA has a one year low of $4.77 and a one year high of $6.15. The firm has a 50-day moving average of $5.78 and a 200-day moving average of $5.68.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at

Get a free copy of the Zacks research report on MDXHealth SA (MXDHF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for MDXHealth SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDXHealth SA and related stocks with our FREE daily email newsletter.